SAB Biotherapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net income of $45.4 million for the third quarter, a substantial turnaround from a net loss of $10.3 million in the same period last year. This improvement was primarily driven by a $61.6 million gain from changes in the fair value of warrant liabilities associated with its Series B Offering. Total operating expenses for the quarter increased to $12.7 million, up from $11.3 million in the prior year, reflecting ongoing investments in research and development.
In terms of revenue, SAB Biotherapeutics did not recognize any revenue for the three and nine months ended September 30, 2025, compared to $1.2 million in grant revenue for the nine months ended September 30, 2024. The absence of revenue was attributed to the termination of various government grants, including a contract with the U.S. Department of Defense. The company anticipates that it will not generate revenue during the development phase of its primary pipeline target, SAB-142, which is focused on treating Type 1 diabetes.
Operationally, SAB Biotherapeutics has made strides in its research and development efforts, with total R&D expenses rising to $23.6 million for the nine months ended September 30, 2025, compared to $22.6 million in the prior year. The increase was driven by higher salaries, clinical trial costs, and animal care expenses. The company is advancing its lead product candidate, SAB-142, into a Phase 2b clinical trial, with plans to hire additional staff to support its development.
As of September 30, 2025, SAB Biotherapeutics reported total assets of $183.4 million, a significant increase from $44.2 million at the end of 2024. This growth was largely due to the successful completion of its Series B Offering, which generated approximately $175 million in gross proceeds. The company ended the quarter with $29.4 million in cash and cash equivalents, up from $8.9 million at the end of 2024, providing a solid liquidity position to support ongoing operations.
Looking ahead, SAB Biotherapeutics expects to continue incurring losses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company plans to explore additional funding options, including equity or debt financings, to support its long-term operational needs. The management remains optimistic about the potential of its proprietary platform and the upcoming clinical trials for SAB-142, which they believe could lead to significant advancements in treating autoimmune disorders.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies (hIgG) for immunology disorders. Its proprietary platform produces targeted, high-potency antibodies using genetically engineered transchromosomic cattle, enabling scalable, plasma-free manufacturing. The company focuses on autoimmune diseases like type 1 diabetes, aiming for disease-modifying therapies with improved safety, re-dosing potential, and addressing unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.